Eisai and PharmStandard sign co-operation agreements in Russia
PharmStandard will handle important stages in the manufacturing of Eisai's oncology and epilepsy medicines
Japanese research and development pharmaceutical company Eisai and Russian pharma firm PharmStandard are to cooperate on localised production of Eisai medicines in Russia.
The agreements relate to Eisai's global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the firm's global epilepsy therapy, Fycompa (perampanel).
Important stages in the manufacturing of eribulin and lenvatinib will be completed in PharmStandard's facilities in Ufa, while the plant in Kursk will handle perampanel.
Eribulin was registered in Russia in July 2012 and became accessible for patients with locally advanced or metastatic breast cancer who have progressed after at least one course of chemotherapy for advanced disease from September 2013.
Lenvatinib was registered in Russia in December 2015 and will be accessible for the treatment of radioactive iodine refractory differentiated thyroid cancer from June this year.
Perampanel was registered in Russia in August 2013 as an adjunctive treatment for patients with partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.
'This is an important step forward for the establishment of Eisai in Russia. Through this arrangement with PharmStandard, we can ensure that Russian patients will have access to our innovative drugs, eribulin, lenvatinib and perampanel.
'Our presence in Russia continues to grow and we are pleased to partner with this leading company to increase our value to patients and their families,' said Olga Konopleva, General Manager, Eisai Russia.